factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Uncommitted | preserve | 62-64 | 62-64 | T4 | in | COEXISTS_WITH | 62 | 64 | preserve | 45-61 | 55-61 | T2 | end-organ damage | DiseaseOrSyndrome | 45 | 61 | preserve | 65-78 | 71-78 | T3 | heart failure | DiseaseOrSyndrome | 65 | 78 | A8 | Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure. | 0-79 | 0 | 79 | Angiotensin-converting enzyme inhibitors and @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 277-279 | 277-279 | T22 | in | TREATS | 277 | 279 | preserve | 262-276 | 266-276 | T12 | ACE inhibitors | PharmacologicSubstance | 262 | 276 | preserve | 280-304 | 297-304 | T13 | congestive heart failure | DiseaseOrSyndrome | 280 | 304 | A9 | The mechanisms of action of ACE inhibitors in congestive heart failure are multiple and may involve important effects on endothelial function in addition to the well known hemodynamic and neurohormonal effects. | 228-456 | 228 | 456 | The mechanisms of action of @SUBJECT$ @PREDICAT$ @OBJECT$ are multiple and may involve important effects on endothelial function in addition to the well known hemodynamic and neurohormonal effects. |
Fact | preserve | 1693-1711 | 1700-1711 | T121 | L-dopa stimulation | USES | 1,693 | 1,711 | preserve | 1700-1711 | 1700-1711 | T118 | stimulation | TherapeuticOrPreventiveProcedure | 1,700 | 1,711 | preserve | 1693-1699 | 1693-1699 | T117 | L-dopa | AminoAcidPeptideOrProtein | 1,693 | 1,699 | A1 | GH response to L-dopa stimulation was blunted in all subjects and it was increased after treatment in both groups. | 1678-1798 | 1,678 | 1,798 | GH response to @OBJECT$ @PREDICAT$ @SUBJECT$ was blunted in all subjects and it was increased after treatment in both groups. |
Fact | preserve | 1256-1273 | 1264-1273 | T94 | placebo treatment | USES | 1,256 | 1,273 | preserve | 1264-1273 | 1264-1273 | T93 | treatment | TherapeuticOrPreventiveProcedure | 1,264 | 1,273 | preserve | 1256-1263 | 1256-1263 | T92 | placebo | MedicalDevice | 1,256 | 1,263 | A2 | GH treatment caused a 1.6-fold increase in the fraction of body weight lost as fat and a greater loss of visceral fat area than placebo treatment (35.3 vs. | 1116-1283 | 1,116 | 1,283 | GH treatment caused a 1.6-fold increase in the fraction of body weight lost as fat and a greater loss of visceral fat area than @OBJECT$ @PREDICAT$ @SUBJECT$ (35.3 vs. |
Fact | preserve | 600-607 | 600-607 | T54 | effects | AFFECTS | 600 | 607 | preserve | 745-757 | 748-757 | T52 | GH secretion | CellFunction | 745 | 757 | preserve | 761-768 | 761-768 | T53 | obesity | DiseaseOrSyndrome | 761 | 768 | A4 | We investigated the effects of GH treatment and dietary restriction on lipolytic and anabolic actions, as well as the consequent changes in insulin and GH secretion in obesity. | 580-769 | 580 | 769 | We investigated the @PREDICAT$ of GH treatment and dietary restriction on lipolytic and anabolic actions, as well as the consequent changes in insulin and @SUBJECT$ in @OBJECT$ . |
Fact | preserve | 2244-2252 | 2244-2252 | T149 | improves | AFFECTS | 2,244 | 2,252 | preserve | 2180-2182 | 2180-2182 | T143 | GH | AminoAcidPeptideOrProtein | 2,180 | 2,182 | preserve | 2253-2265 | 2256-2265 | T148 | GH secretion | CellFunction | 2,253 | 2,265 | A5 | This study demonstrates that in obese subjects given a hypocaloric diet, GH accelerates body fat loss, exerts anabolic effects and improves GH secretion. | 2101-2266 | 2,101 | 2,266 | This study demonstrates that in obese subjects given a hypocaloric diet, @SUBJECT$ accelerates body fat loss, exerts anabolic effects and @PREDICAT$ @OBJECT$ . |
Probable | preserve | 209-215 | 209-215 | T18 | induce | CAUSES | 209 | 215 | preserve | 185-199 | 192-199 | T15 | Growth hormone | AminoAcidPeptideOrProtein | 185 | 199 | preserve | 231-240 | 231-240 | T17 | lipolysis | OrganismFunction | 231 | 240 | A6 | Growth hormone (GH) can induce an accelerated lipolysis. | 185-241 | 185 | 241 | @SUBJECT$ (GH) can @PREDICAT$ an accelerated @OBJECT$ . |
Fact | preserve | 934-941 | 934-941 | T81 | treated | TREATS | 934 | 941 | preserve | 947-973 | 971-973 | T71 | recombinant human GH | AminoAcidPeptideOrProtein | 947 | 973 | preserve | 773-778 | 773-778 | T56 | obese | DiseaseOrSyndrome | 773 | 778 | A7 | 24 obese subjects (22 women and 2 men; 22-46 years old) were fed a diet of 25 kcal/kg ideal body weight (IBW) with 1.2 g protein/kg IBW daily and were treated with recombinant human GH (n = 12, 0.18 U/kg IBW/week) or placebo (n = 12, vehicle injection) in a 12-week randomized, double-blind and placebo-controlled trial. | 770-1115 | 770 | 1,115 | 24 @OBJECT$ subjects (22 women and 2 men; 22-46 years old) were fed a diet of 25 kcal/kg ideal body weight (IBW) with 1.2 g protein/kg IBW daily and were @PREDICAT$ with @SUBJECT$ (n = 12, 0.18 U/kg IBW/week) or placebo (n = 12, vehicle injection) in a 12-week randomized, double-blind and placebo-controlled trial. |
Fact | preserve | 2364-2367 | 2364-2367 | T158 | for | TREATS | 2,364 | 2,367 | preserve | 2344-2363 | 2352-2363 | T156 | caloric restriction | TherapeuticOrPreventiveProcedure | 2,344 | 2,363 | preserve | 2368-2375 | 2368-2375 | T157 | obesity | DiseaseOrSyndrome | 2,368 | 2,375 | A8 | These findings suggest a possible therapeutic role of low-dose GH with caloric restriction for obesity. | 2267-2376 | 2,267 | 2,376 | These findings suggest a possible therapeutic role of low-dose GH with @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 384-393 | 384-393 | T37 | treatment | TREATS | 384 | 393 | preserve | 346-372 | 361-372 | T29 | Dietary restriction | TherapeuticOrPreventiveProcedure | 346 | 372 | preserve | 398-405 | 398-405 | T31 | obesity | DiseaseOrSyndrome | 398 | 405 | A9 | Dietary restriction as a basic treatment for obesity is complicated by poor compliance, protein catabolism, and slow rates or weight loss. | 346-497 | 346 | 497 | @SUBJECT$ as a basic @PREDICAT$ for @OBJECT$ is complicated by poor compliance, protein catabolism, and slow rates or weight loss. |
Fact | preserve | 332-338 | 332-338 | T28 | effect | AFFECTS | 332 | 338 | preserve | 342-344 | 342-344 | T26 | GH | AminoAcidPeptideOrProtein | 342 | 344 | preserve | 322-331 | 322-331 | T24 | lipolytic | OrganismFunction | 322 | 331 | A10 | Impaired secretion of GH in obesity results in the consequent loss of the lipolytic effect of GH. | 242-345 | 242 | 345 | Impaired secretion of GH in obesity results in the consequent loss of the @OBJECT$ @PREDICAT$ of @SUBJECT$ . |
Fact | preserve | 171-183 | 177-183 | T13 | obese adults | PROCESS_OF | 171 | 183 | preserve | 171-176 | 171-176 | T10 | obese | DiseaseOrSyndrome | 171 | 176 | preserve | 177-183 | 177-183 | T11 | adults | AgeGroup | 177 | 183 | A11 | Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. | 0-184 | 0 | 184 | Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1592-1605 | 1595-1605 | T114 | GH injections | USES | 1,592 | 1,605 | preserve | 1595-1605 | 1595-1605 | T109 | injections | TherapeuticOrPreventiveProcedure | 1,595 | 1,605 | preserve | 1592-1594 | 1592-1594 | T108 | GH | AminoAcidPeptideOrProtein | 1,592 | 1,594 | A13 | GH injections caused a 1.6-fold increase in IGF-I, despite caloric restriction. | 1592-1677 | 1,592 | 1,677 | @OBJECT$ @PREDICAT$ @SUBJECT$ caused a 1.6-fold increase in IGF-I, despite caloric restriction. |
Fact | preserve | 116-124 | 116-124 | T12 | improves | TREATS | 116 | 124 | preserve | 39-55 | 44-55 | T3 | diet restriction | TherapeuticOrPreventiveProcedure | 39 | 55 | preserve | 150-161 | 150-161 | T9 | dysfunction | PathologicFunction | 150 | 161 | A14 | Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. | 0-184 | 0 | 184 | Low-dose growth hormone treatment with @SUBJECT$ accelerates body fat loss, exerts anabolic effect and @PREDICAT$ growth hormone secretory @OBJECT$ in obese adults. |
Fact | preserve | 162-164 | 162-164 | T14 | in | PROCESS_OF | 162 | 164 | preserve | 150-161 | 150-161 | T9 | dysfunction | PathologicFunction | 150 | 161 | preserve | 177-183 | 177-183 | T11 | adults | AgeGroup | 177 | 183 | A15 | Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. | 0-184 | 0 | 184 | Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory @SUBJECT$ @PREDICAT$ obese @OBJECT$ . |
Fact | preserve | 273-275 | 273-275 | T27 | in | ASSOCIATED_WITH | 273 | 275 | preserve | 264-266 | 264-266 | T21 | GH | AminoAcidPeptideOrProtein | 264 | 266 | preserve | 276-283 | 276-283 | T22 | obesity | DiseaseOrSyndrome | 276 | 283 | A17 | Impaired secretion of GH in obesity results in the consequent loss of the lipolytic effect of GH. | 242-345 | 242 | 345 | Impaired secretion of @SUBJECT$ @PREDICAT$ @OBJECT$ results in the consequent loss of the lipolytic effect of GH. |
Fact | preserve | 2102-2104 | 2102-2104 | T117 | in | PROCESS_OF | 2,102 | 2,104 | preserve | 2023-2048 | 2038-2048 | T106 | Carotid artery thrombosis | DiseaseOrSyndrome | 2,023 | 2,048 | preserve | 2105-2113 | 2105-2113 | T111 | patients | PatientOrDisabledGroup | 2,105 | 2,113 | A1 | CONCLUSION: Carotid artery thrombosis during immediate reoperation was more frequent in patients who had an early postoperative stroke than in patients who had an intraoperative stroke. | 2011-2209 | 2,011 | 2,209 | CONCLUSION: @SUBJECT$ during immediate reoperation was more frequent @PREDICAT$ @OBJECT$ who had an early postoperative stroke than in patients who had an intraoperative stroke. |
Fact | preserve | 2118-2121 | 2118-2121 | T118 | had | PROCESS_OF | 2,118 | 2,121 | preserve | 2131-2151 | 2145-2151 | T113 | postoperative stroke | DiseaseOrSyndrome | 2,131 | 2,151 | preserve | 2105-2113 | 2105-2113 | T111 | patients | PatientOrDisabledGroup | 2,105 | 2,113 | A2 | CONCLUSION: Carotid artery thrombosis during immediate reoperation was more frequent in patients who had an early postoperative stroke than in patients who had an intraoperative stroke. | 2011-2209 | 2,011 | 2,209 | CONCLUSION: Carotid artery thrombosis during immediate reoperation was more frequent in @OBJECT$ who @PREDICAT$ an early @SUBJECT$ than in patients who had an intraoperative stroke. |
Fact | preserve | 2239-2242 | 2239-2242 | T126 | had | PROCESS_OF | 2,239 | 2,242 | preserve | 2267-2273 | 2267-2273 | T122 | stroke | DiseaseOrSyndrome | 2,267 | 2,273 | preserve | 2226-2234 | 2226-2234 | T120 | patients | PatientOrDisabledGroup | 2,226 | 2,234 | A3 | It appears that patients who had an intraoperative stroke have a higher incidence of uncorrectable lesions. | 2210-2323 | 2,210 | 2,323 | It appears that @OBJECT$ who @PREDICAT$ an intraoperative @SUBJECT$ have a higher incidence of uncorrectable lesions. |
Fact | preserve | 362-365 | 362-365 | T26 | had | PROCESS_OF | 362 | 365 | preserve | 375-395 | 389-395 | T24 | postoperative stroke | DiseaseOrSyndrome | 375 | 395 | preserve | 349-357 | 349-357 | T22 | patients | PatientOrDisabledGroup | 349 | 357 | A4 | PURPOSE: After carotid endarterectomy, intraoperative findings and outcome of immediate reoperation of patients who had an intraoperative stroke were compared with those of patients who had an early postoperative stroke. | 163-396 | 163 | 396 | PURPOSE: After carotid endarterectomy, intraoperative findings and outcome of immediate reoperation of patients who had an intraoperative stroke were compared with those of @OBJECT$ who @PREDICAT$ an early @SUBJECT$ . |
Fact | preserve | 915-935 | 926-935 | T78 | thrombotic occlusion | LOCATION_OF | 915 | 935 | preserve | 943-957 | 951-957 | T49 | carotid artery | BodyPartOrganOrOrganComponent | 943 | 957 | preserve | 915-925 | 915-925 | T47 | thrombotic | DiseaseOrSyndrome | 915 | 925 | A5 | RESULTS: Positive intraoperative findings that could be corrected during immediate reoperation were: (1) thrombotic occlusion of the carotid artery that was operated on caused by technical error, which was found in nine of 41 patients (22%) in group A and in 11 of 18 patients (61%) in group B (P =.009); (2) mural thrombus caused by technical error without occlusion, which was detected in seven of 41 patients (17%) in group A and in two of 18 patients (11%) in group B (P >.05); and (3) technical error without a thrombus, which was found in eight of 41 patients (20%) in group A and in three of 18 patients (17%) in group B (P >.05). | 798-1483 | 798 | 1,483 | RESULTS: Positive intraoperative findings that could be corrected during immediate reoperation were: (1) @OBJECT$ @PREDICAT$ of the @SUBJECT$ that was operated on caused by technical error, which was found in nine of 41 patients (22%) in group A and in 11 of 18 patients (61%) in group B (P =.009); (2) mural thrombus caused by technical error without occlusion, which was detected in seven of 41 patients (17%) in group A and in two of 18 patients (11%) in group B (P >.05); and (3) technical error without a thrombus, which was found in eight of 41 patients (20%) in group A and in three of 18 patients (17%) in group B (P >.05). |
Fact | preserve | 936-938 | 936-938 | T77 | of | LOCATION_OF | 936 | 938 | preserve | 943-957 | 951-957 | T49 | carotid artery | BodyPartOrganOrOrganComponent | 943 | 957 | preserve | 926-935 | 926-935 | T48 | occlusion | PathologicFunction | 926 | 935 | A6 | RESULTS: Positive intraoperative findings that could be corrected during immediate reoperation were: (1) thrombotic occlusion of the carotid artery that was operated on caused by technical error, which was found in nine of 41 patients (22%) in group A and in 11 of 18 patients (61%) in group B (P =.009); (2) mural thrombus caused by technical error without occlusion, which was detected in seven of 41 patients (17%) in group A and in two of 18 patients (11%) in group B (P >.05); and (3) technical error without a thrombus, which was found in eight of 41 patients (20%) in group A and in three of 18 patients (17%) in group B (P >.05). | 798-1483 | 798 | 1,483 | RESULTS: Positive intraoperative findings that could be corrected during immediate reoperation were: (1) thrombotic @OBJECT$ @PREDICAT$ the @SUBJECT$ that was operated on caused by technical error, which was found in nine of 41 patients (22%) in group A and in 11 of 18 patients (61%) in group B (P =.009); (2) mural thrombus caused by technical error without occlusion, which was detected in seven of 41 patients (17%) in group A and in two of 18 patients (11%) in group B (P >.05); and (3) technical error without a thrombus, which was found in eight of 41 patients (20%) in group A and in three of 18 patients (17%) in group B (P >.05). |
Probable | preserve | 2274-2278 | 2274-2278 | T127 | have | PROCESS_OF | 2,274 | 2,278 | preserve | 2315-2322 | 2315-2322 | T125 | lesions | Finding | 2,315 | 2,322 | preserve | 2226-2234 | 2226-2234 | T120 | patients | PatientOrDisabledGroup | 2,226 | 2,234 | A8 | It appears that patients who had an intraoperative stroke have a higher incidence of uncorrectable lesions. | 2210-2323 | 2,210 | 2,323 | It appears that @OBJECT$ who had an intraoperative stroke @PREDICAT$ a higher incidence of uncorrectable @SUBJECT$ . |
Fact | preserve | 22-25 | 22-25 | T10 | for | TREATS | 22 | 25 | preserve | 10-21 | 10-21 | T2 | reoperation | TherapeuticOrPreventiveProcedure | 10 | 21 | preserve | 40-46 | 40-46 | T4 | stroke | DiseaseOrSyndrome | 40 | 46 | A9 | Immediate reoperation for perioperative stroke after 2250 carotid endarterectomies: differences between intraoperative and early postoperative stroke. | 0-162 | 0 | 162 | Immediate @SUBJECT$ @PREDICAT$ perioperative @OBJECT$ after 2250 carotid endarterectomies: differences between intraoperative and early postoperative stroke. |
Fact | preserve | 285-288 | 285-288 | T25 | had | PROCESS_OF | 285 | 288 | preserve | 307-313 | 307-313 | T21 | stroke | DiseaseOrSyndrome | 307 | 313 | preserve | 272-280 | 272-280 | T19 | patients | PatientOrDisabledGroup | 272 | 280 | A10 | PURPOSE: After carotid endarterectomy, intraoperative findings and outcome of immediate reoperation of patients who had an intraoperative stroke were compared with those of patients who had an early postoperative stroke. | 163-396 | 163 | 396 | PURPOSE: After carotid endarterectomy, intraoperative findings and outcome of immediate reoperation of @OBJECT$ who @PREDICAT$ an intraoperative @SUBJECT$ were compared with those of patients who had an early postoperative stroke. |
Fact | preserve | 2180-2183 | 2180-2183 | T119 | had | PROCESS_OF | 2,180 | 2,183 | preserve | 2202-2208 | 2202-2208 | T116 | stroke | DiseaseOrSyndrome | 2,202 | 2,208 | preserve | 2160-2168 | 2160-2168 | T114 | patients | PatientOrDisabledGroup | 2,160 | 2,168 | A11 | CONCLUSION: Carotid artery thrombosis during immediate reoperation was more frequent in patients who had an early postoperative stroke than in patients who had an intraoperative stroke. | 2011-2209 | 2,011 | 2,209 | CONCLUSION: Carotid artery thrombosis during immediate reoperation was more frequent in patients who had an early postoperative stroke than in @OBJECT$ who @PREDICAT$ an intraoperative @SUBJECT$ . |
Fact | preserve | 915-935 | 926-935 | T76 | thrombotic occlusion | ISA | 915 | 935 | preserve | 915-925 | 915-925 | T47 | thrombotic | DiseaseOrSyndrome | 915 | 925 | preserve | 926-935 | 926-935 | T48 | occlusion | PathologicFunction | 926 | 935 | A12 | RESULTS: Positive intraoperative findings that could be corrected during immediate reoperation were: (1) thrombotic occlusion of the carotid artery that was operated on caused by technical error, which was found in nine of 41 patients (22%) in group A and in 11 of 18 patients (61%) in group B (P =.009); (2) mural thrombus caused by technical error without occlusion, which was detected in seven of 41 patients (17%) in group A and in two of 18 patients (11%) in group B (P >.05); and (3) technical error without a thrombus, which was found in eight of 41 patients (20%) in group A and in three of 18 patients (17%) in group B (P >.05). | 798-1483 | 798 | 1,483 | RESULTS: Positive intraoperative findings that could be corrected during immediate reoperation were: (1) @SUBJECT$ @PREDICAT$ @OBJECT$ of the carotid artery that was operated on caused by technical error, which was found in nine of 41 patients (22%) in group A and in 11 of 18 patients (61%) in group B (P =.009); (2) mural thrombus caused by technical error without occlusion, which was detected in seven of 41 patients (17%) in group A and in two of 18 patients (11%) in group B (P >.05); and (3) technical error without a thrombus, which was found in eight of 41 patients (20%) in group A and in three of 18 patients (17%) in group B (P >.05). |
Fact | preserve | 513-522 | 513-522 | T41 | treatment | TREATS | 513 | 522 | preserve | 392-400 | 392-400 | T22 | atenolol | OrganicChemical | 392 | 400 | preserve | 526-538 | 526-538 | T29 | hypertension | DiseaseOrSyndrome | 526 | 538 | A1 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, @SUBJECT$ , labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the @PREDICAT$ of @OBJECT$ , in urine samples. |
Fact | preserve | 513-522 | 513-522 | T41 | treatment | TREATS | 513 | 522 | preserve | 413-423 | 413-423 | T24 | metoprolol | OrganicChemical | 413 | 423 | preserve | 526-538 | 526-538 | T29 | hypertension | DiseaseOrSyndrome | 526 | 538 | A2 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, @SUBJECT$ , nadolol, and propranolol), which are usually administered in combinations for the @PREDICAT$ of @OBJECT$ , in urine samples. |
Fact | preserve | 359-390 | 380-390 | T35 | beta-blockers (acebutolol | ISA | 359 | 390 | preserve | 413-423 | 413-423 | T24 | metoprolol | OrganicChemical | 413 | 423 | preserve | 359-372 | 359-372 | T20 | beta-blockers | PharmacologicSubstance | 359 | 372 | A3 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 @OBJECT$ @PREDICAT$ , atenolol, labetalol, @SUBJECT$ , nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 540-542 | 540-542 | T47 | in | LOCATION_OF | 540 | 542 | preserve | 549-562 | 555-562 | T30 | urine samples | BodySubstance | 549 | 562 | preserve | 261-269 | 261-269 | T14 | mixtures | Substance | 261 | 269 | A4 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of @OBJECT$ of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 359-390 | 380-390 | T35 | beta-blockers (acebutolol | ISA | 359 | 390 | preserve | 402-411 | 402-411 | T23 | labetalol | OrganicChemical | 402 | 411 | preserve | 359-372 | 359-372 | T20 | beta-blockers | PharmacologicSubstance | 359 | 372 | A5 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 @OBJECT$ @PREDICAT$ , atenolol, @SUBJECT$ , metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 275-301 | 292-301 | T31 | diuretics (amiloride | ISA | 275 | 301 | preserve | 340-351 | 340-351 | T19 | triamterene | OrganicChemical | 340 | 351 | preserve | 275-284 | 275-284 | T15 | diuretics | PharmacologicSubstance | 275 | 284 | A6 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 @OBJECT$ @PREDICAT$ , bendroflumethiazide, piretanide, and @SUBJECT$ ) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 513-522 | 513-522 | T41 | treatment | TREATS | 513 | 522 | preserve | 438-449 | 438-449 | T26 | propranolol | OrganicChemical | 438 | 449 | preserve | 526-538 | 526-538 | T29 | hypertension | DiseaseOrSyndrome | 526 | 538 | A7 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and @SUBJECT$ ), which are usually administered in combinations for the @PREDICAT$ of @OBJECT$ , in urine samples. |
Fact | preserve | 359-390 | 380-390 | T35 | beta-blockers (acebutolol | ISA | 359 | 390 | preserve | 425-432 | 425-432 | T25 | nadolol | OrganicChemical | 425 | 432 | preserve | 359-372 | 359-372 | T20 | beta-blockers | PharmacologicSubstance | 359 | 372 | A9 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 @OBJECT$ @PREDICAT$ , atenolol, labetalol, metoprolol, @SUBJECT$ , and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 359-390 | 380-390 | T35 | beta-blockers (acebutolol | ISA | 359 | 390 | preserve | 438-449 | 438-449 | T26 | propranolol | OrganicChemical | 438 | 449 | preserve | 359-372 | 359-372 | T20 | beta-blockers | PharmacologicSubstance | 359 | 372 | A10 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 @OBJECT$ @PREDICAT$ , atenolol, labetalol, metoprolol, nadolol, and @SUBJECT$ ), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 275-301 | 292-301 | T31 | diuretics (amiloride | ISA | 275 | 301 | preserve | 324-334 | 324-334 | T18 | piretanide | OrganicChemical | 324 | 334 | preserve | 275-284 | 275-284 | T15 | diuretics | PharmacologicSubstance | 275 | 284 | A11 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 @OBJECT$ @PREDICAT$ , bendroflumethiazide, @SUBJECT$ , and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 513-522 | 513-522 | T41 | treatment | TREATS | 513 | 522 | preserve | 425-432 | 425-432 | T25 | nadolol | OrganicChemical | 425 | 432 | preserve | 526-538 | 526-538 | T29 | hypertension | DiseaseOrSyndrome | 526 | 538 | A13 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, @SUBJECT$ , and propranolol), which are usually administered in combinations for the @PREDICAT$ of @OBJECT$ , in urine samples. |
Fact | preserve | 275-301 | 292-301 | T31 | diuretics (amiloride | ISA | 275 | 301 | preserve | 292-301 | 292-301 | T16 | amiloride | OrganicChemical | 292 | 301 | preserve | 275-284 | 275-284 | T15 | diuretics | PharmacologicSubstance | 275 | 284 | A14 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 @OBJECT$ @PREDICAT$ @SUBJECT$ , bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 513-522 | 513-522 | T41 | treatment | TREATS | 513 | 522 | preserve | 402-411 | 402-411 | T23 | labetalol | OrganicChemical | 402 | 411 | preserve | 526-538 | 526-538 | T29 | hypertension | DiseaseOrSyndrome | 526 | 538 | A15 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, @SUBJECT$ , metoprolol, nadolol, and propranolol), which are usually administered in combinations for the @PREDICAT$ of @OBJECT$ , in urine samples. |
Fact | preserve | 275-301 | 292-301 | T31 | diuretics (amiloride | ISA | 275 | 301 | preserve | 303-322 | 303-322 | T17 | bendroflumethiazide | OrganicChemical | 303 | 322 | preserve | 275-284 | 275-284 | T15 | diuretics | PharmacologicSubstance | 275 | 284 | A16 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 @OBJECT$ @PREDICAT$ , @SUBJECT$ , piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 359-390 | 380-390 | T35 | beta-blockers (acebutolol | ISA | 359 | 390 | preserve | 392-400 | 392-400 | T22 | atenolol | OrganicChemical | 392 | 400 | preserve | 359-372 | 359-372 | T20 | beta-blockers | PharmacologicSubstance | 359 | 372 | A17 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 @OBJECT$ @PREDICAT$ , @SUBJECT$ , labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 359-390 | 380-390 | T35 | beta-blockers (acebutolol | ISA | 359 | 390 | preserve | 380-390 | 380-390 | T21 | acebutolol | OrganicChemical | 380 | 390 | preserve | 359-372 | 359-372 | T20 | beta-blockers | PharmacologicSubstance | 359 | 372 | A18 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 @OBJECT$ @PREDICAT$ @SUBJECT$ , atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. |
Fact | preserve | 513-522 | 513-522 | T41 | treatment | TREATS | 513 | 522 | preserve | 380-390 | 380-390 | T21 | acebutolol | OrganicChemical | 380 | 390 | preserve | 526-538 | 526-538 | T29 | hypertension | DiseaseOrSyndrome | 526 | 538 | A20 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers (acebutolol, atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the treatment of hypertension, in urine samples. | 127-563 | 127 | 563 | A simple direct injection chromatographic procedure with fluorimetric detection is successfully applied to the determination of mixtures of 4 diuretics (amiloride, bendroflumethiazide, piretanide, and triamterene) and 6 beta-blockers ( @SUBJECT$ , atenolol, labetalol, metoprolol, nadolol, and propranolol), which are usually administered in combinations for the @PREDICAT$ of @OBJECT$ , in urine samples. |
Fact | preserve | 830-833 | 830-833 | T50 | had | PROCESS_OF | 830 | 833 | preserve | 834-862 | 855-862 | T47 | intra-aortic balloon rupture | DiseaseOrSyndrome | 834 | 862 | preserve | 807-815 | 807-815 | T46 | patients | PatientOrDisabledGroup | 807 | 815 | A1 | While the IABP was in place, three patients (3.3%) had femoral artery emboli, four patients (4.4%) had lower extremity ischemia that resolved after the removal of the balloon, eight patients (8.8%) had groin hematoma requiring blood transfusion (< or =2 units) and four patients (4.4%) had intra-aortic balloon rupture. | 519-863 | 519 | 863 | While the IABP was in place, three patients (3.3%) had femoral artery emboli, four patients (4.4%) had lower extremity ischemia that resolved after the removal of the balloon, eight patients (8.8%) had groin hematoma requiring blood transfusion (< or =2 units) and four @OBJECT$ (4.4%) @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 624-627 | 624-627 | T49 | had | PROCESS_OF | 624 | 627 | preserve | 628-658 | 650-658 | T36 | lower extremity ischemia | PathologicFunction | 628 | 658 | preserve | 608-616 | 608-616 | T35 | patients | PatientOrDisabledGroup | 608 | 616 | A5 | While the IABP was in place, three patients (3.3%) had femoral artery emboli, four patients (4.4%) had lower extremity ischemia that resolved after the removal of the balloon, eight patients (8.8%) had groin hematoma requiring blood transfusion (< or =2 units) and four patients (4.4%) had intra-aortic balloon rupture. | 519-863 | 519 | 863 | While the IABP was in place, three patients (3.3%) had femoral artery emboli, four @OBJECT$ (4.4%) @PREDICAT$ @SUBJECT$ that resolved after the removal of the balloon, eight patients (8.8%) had groin hematoma requiring blood transfusion (< or =2 units) and four patients (4.4%) had intra-aortic balloon rupture. |
Fact | preserve | 576-579 | 576-579 | T48 | had | PROCESS_OF | 576 | 579 | preserve | 580-601 | 595-601 | T33 | femoral artery emboli | DiseaseOrSyndrome | 580 | 601 | preserve | 554-562 | 554-562 | T31 | patients | PatientOrDisabledGroup | 554 | 562 | A6 | While the IABP was in place, three patients (3.3%) had femoral artery emboli, four patients (4.4%) had lower extremity ischemia that resolved after the removal of the balloon, eight patients (8.8%) had groin hematoma requiring blood transfusion (< or =2 units) and four patients (4.4%) had intra-aortic balloon rupture. | 519-863 | 519 | 863 | While the IABP was in place, three @OBJECT$ (3.3%) @PREDICAT$ @SUBJECT$ , four patients (4.4%) had lower extremity ischemia that resolved after the removal of the balloon, eight patients (8.8%) had groin hematoma requiring blood transfusion (< or =2 units) and four patients (4.4%) had intra-aortic balloon rupture. |
Fact | preserve | 208-213 | 208-213 | T19 | after | PRECEDES | 208 | 213 | preserve | 214-240 | 233-240 | T13 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 214 | 240 | preserve | 88-104 | 88-104 | T7 | counterpulsation | TherapeuticOrPreventiveProcedure | 88 | 104 | A8 | Intra-aortic balloon counterpulsation (IABP) related complications in a heterogeneous group of patients who received an IABP before or after thrombolytic therapy and mechanical revascularization or in the management of refractory unstable angina and myocardial infarction related mechanical complications were evaluated prospectively. | 67-425 | 67 | 425 | Intra-aortic balloon @OBJECT$ (IABP) related complications in a heterogeneous group of patients who received an IABP before or @PREDICAT$ @SUBJECT$ and mechanical revascularization or in the management of refractory unstable angina and myocardial infarction related mechanical complications were evaluated prospectively. |
Probable | preserve | 1389-1400 | 1389-1400 | T87 | complicated | COMPLICATES | 1,389 | 1,400 | preserve | 1406-1436 | 1428-1436 | T86 | lower extremity ischemia | PathologicFunction | 1,406 | 1,436 | preserve | 1340-1360 | 1340-1360 | T83 | hypercholesterolemia | DiseaseOrSyndrome | 1,340 | 1,360 | A10 | four patients; 4.9% of heparin group, P = 0.005) and hypercholesterolemia (>200 mg/dl) was more often complicated with lower extremity ischemia (P = 0.017). | 1281-1449 | 1,281 | 1,449 | four patients; 4.9% of heparin group, P = 0.005) and @OBJECT$ (>200 mg/dl) was more often @PREDICAT$ with @SUBJECT$ (P = 0.017). |